MedTrace Logo

Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10

NCT07621393 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-06-04

No results posted yet for this study

Summary

This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg/m². The objective is to comprehensively evaluate the potential of DNF-10 to modulate appetite through the regulation of enteroendocrine hormones and to determine its relevance in human physiology.

Conditions

  • Healthy Adult

Interventions

DIETARY_SUPPLEMENT

DNF-10: 250 mg/day

DNF-10

OTHER

Placebo: 250 mg maltodextrin/day

Placebo

Sponsors & Collaborators

  • Centros de Investigación de Nutrición y Salud

    collaborator OTHER

  • Fytexia

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-12
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07621393 on ClinicalTrials.gov